Press releases
- Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- Insmed To Present at the Goldman Sachs 45th Annual Global Healthcare Conference
- Insmed to Host Commercial Webinar on June 4, 2024
- Insmed Announces Pricing of $650 Million Public Offering of Common Stock
- Insmed Announces Proposed $500 Million Public Offering of Common Stock
- Insmed Announces Positive Topline Results from Landmark ASPEN Study of Brensocatib in Patients with Bronchiectasis
- Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis
- Insmed Presents Positive Patient-Reported Outcomes and Microbiologic Data from Phase 3 ARISE Study Of ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in Patients with NTM Lung Disease Caused by MAC at American Thoracic Society 2024 International Conference Plenary Session
- Insmed Reports First-Quarter 2024 Financial Results and Provides Business Update
- Insmed To Present at the BofA Securities Health Care Conference 2024
More ▼
Key statistics
On Friday, Insmed Inc (IM8N:DUS) closed at 51.50, -3.74% below its 52-week high of 53.50, set on May 30, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 52.00 |
---|---|
High | 52.50 |
Low | 51.50 |
Bid | 52.00 |
Offer | 53.50 |
Previous close | 52.50 |
Average volume | 94.60 |
---|---|
Shares outstanding | 163.08m |
Free float | 161.43m |
P/E (TTM) | -- |
Market cap | 9.43bn USD |
EPS (TTM) | -5.23 USD |
Data delayed at least 15 minutes, as of Jun 07 2024 18:31 BST.
More ▼